Skip to main content

Avzivi FDA Approval History

Last updated by Judith Stewart, BPharm on Dec 11, 2023.

FDA Approved: Yes (First approved December 6, 2023)
Brand name: Avzivi
Generic name: bevacizumab-tnjn
Dosage form: Injection
Company: Bio-Thera Solutions, Ltd.
Treatment for: Colorectal Cancer, Non Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Avzivi is a vascular endothelial growth factor inhibitor biosimilar to Avastin used for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Development timeline for Avzivi

DateArticle
Dec  7, 2023Approval FDA Approves Avzivi (bevacizumab-tnjn), a Biosimilar to Avastin
Dec 28, 2020Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.